Brief: Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial
11/01/2018 14:33
Jan 11 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX RECEIVES FDA PROTOCOL ACCEPTANCE FOR THE
ONGOING
PHASE 3 BETONMACE TRIAL
* RESVERLOGIX CORP - BETONMACE TOP LINE DATA IS STILL
PLANNED TO
BE AVAILABLE AROUND END OF 2018
* RESVERLOGIX - BETONMACE TRIAL WILL NOW BE EXPANDED TO
NORTH
AMERICA
Source text for Eikon: ID:nGNXOLRWXa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment